Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celldex Therapeutics (CLDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 412,050
  • Shares Outstanding, K 135,990
  • Annual Sales, $ 6,790 K
  • Annual Income, $ -128,530 K
  • 36-Month Beta 2.72
  • Price/Sales 58.71
  • Price/Cash Flow N/A
  • Price/Book 1.72

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.64 +16.29%
on 11/13/17
3.09 -0.65%
on 12/11/17
+0.34 (+12.45%)
since 11/10/17
3-Month
2.31 +32.90%
on 11/02/17
3.26 -5.83%
on 10/09/17
+0.38 (+14.13%)
since 09/11/17
52-Week
2.20 +39.55%
on 06/08/17
4.07 -24.57%
on 12/19/16
-0.68 (-18.13%)
since 12/09/16

Most Recent Stories

More News
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140

Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.

CORT : 17.19 (+2.38%)
CLDX : 3.07 (+1.32%)
ACHN : 2.93 (+1.03%)
BMY : 62.79 (+0.59%)
Cancer Space Update: Pfizer's Bavencio Fails in Phase III

The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.

MYL : 39.01 (+0.88%)
CLDX : 3.07 (+1.32%)
ESALY : 58.5800 (+1.71%)
AZN : 32.97 (+0.70%)
RHHBY : 30.3700 (+0.50%)
PFE : 35.96 (+0.62%)
BMY : 62.79 (+0.59%)
Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label, Phase 1 study of CDX-1140 in patients with advanced solid tumors. CDX-1140 is a fully human antibody...

CLDX : 3.07 (+1.32%)
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU

This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.

CLDX : 3.07 (+1.32%)
AZN : 32.97 (+0.70%)
JNJ : 140.02 (-0.41%)
MRK : 56.39 (+1.48%)
LLY : 86.61 (+0.19%)
NVS : 83.89 (-0.08%)
RHHBY : 30.3700 (+0.50%)
Featured Company News - Celldex Starts Phase-2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Research Desk Line-up: Abeona Therapeutics Post Earnings Coverage

CLDX : 3.07 (+1.32%)
ABEO : 15.80 (-2.47%)
LLY : 86.61 (+0.19%)
Breakfast Technical Briefing on Biotech Stocks -- Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, and Cytokinetics

If you want a Stock Review on CALA, CLDX, CLVS, or CYTK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. Pre-market, DailyStockTracker.com dedicates...

CLDX : 3.07 (+1.32%)
CYTK : 7.95 (-0.62%)
CLVS : 62.48 (+0.53%)
CALA : 9.30 (-2.11%)
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate

Celldex (CLDX) enrolled the first patient in a phase II study on pipeline candidate, CDX-3379, to evaluate it in advanced head and neck squamous cell carcinoma patients.

CLDX : 3.07 (+1.32%)
MRK : 56.39 (+1.48%)
LLY : 86.61 (+0.19%)
BMY : 62.79 (+0.59%)
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma

Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its open-label Phase 2 study of CDX-3379 in combination with cetuximab in patients with cetuximab-refractory, advanced...

CLDX : 3.07 (+1.32%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 3.07 (+1.32%)
ARQL : 1.50 (-0.66%)
RGBP : 0.0659 (-11.54%)
RGBPP : 0.0560 (unch)
ECYT : 4.94 (+0.20%)
CASI : 3.42 (-1.16%)
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up

Celldex Therapeutics, Inc. (CLDX) reported narrower-than-expected loss in Q3 and also beat estimates for sales. Shares rose in after-hours trading on Tuesday.

CLDX : 3.07 (+1.32%)
MRK : 56.39 (+1.48%)
LLY : 86.61 (+0.19%)
BMY : 62.79 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

2nd Resistance Point 3.07
1st Resistance Point 3.05
Last Price 3.07
1st Support Level 2.99
2nd Support Level 2.95

See More

52-Week High 4.07
Fibonacci 61.8% 3.36
Fibonacci 50% 3.14
Last Price 3.07
Fibonacci 38.2% 2.91
52-Week Low 2.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.